{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:27:44Z","timestamp":1790404064884,"version":"4.1.0"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.0980","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T16:34:33Z","timestamp":1615307673000},"page":"e210980","source":"Crossref","is-referenced-by-count":25,"title":["Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors"],"prefix":"10.1001","volume":"4","author":[{"given":"Jessica J.","family":"Waninger","sequence":"first","affiliation":[{"name":"University of Michigan Medical School, University of Michigan, Ann Arbor"},{"name":"Department of Cellular and Molecular Biology, University of Michigan, Ann Arbor"},{"name":"Michigan Center for Translational Pathology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent T.","family":"Ma","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Journey","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Skvarce","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoey","family":"Chopra","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alangoya","family":"Tezel","sequence":"additional","affiliation":[{"name":"University of Michigan Medical School, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex K.","family":"Bryant","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mayo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"},{"name":"Department of Biostatistics, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamya","family":"Sankar","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Ramnath","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor"},{"name":"Department of Hematology Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Lao","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor"},{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy B.","family":"Sussman","sequence":"additional","affiliation":[{"name":"Department of Medicine, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Fecher","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor"},{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajjai","family":"Alva","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor"},{"name":"Department of Hematology Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Michigan, Ann Arbor"},{"name":"Rogel Cancer Center, University of Michigan, Ann Arbor"},{"name":"Department of Radiation Oncology, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2021,3,9]]},"reference":[{"issue":"8","key":"zoi210049r1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi210049r2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi210049r3","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"zoi210049r4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3215","key":"zoi210049r5","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","article-title":"On respiratory impairment in cancer cells.","volume":"124","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"12","key":"zoi210049r6","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1002\/cam4.2018.7.issue-12","article-title":"Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy.","volume":"7","author":"Feng","year":"2018","journal-title":"Cancer Med"},{"issue":"6","key":"zoi210049r7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis.","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"issue":"3","key":"zoi210049r8","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.4049\/jimmunol.1202702","article-title":"Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells.","volume":"191","author":"Husain","year":"2013","journal-title":"J Immunol"},{"issue":"1","key":"zoi210049r9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1186\/s12885-019-6073-7","article-title":"Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.","volume":"19","author":"Bilen","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"zoi210049r10","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination.","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"4","key":"zoi210049r11","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.adro.2016.10.001","article-title":"The big data effort in radiation oncology: data mining or data farming?","volume":"1","author":"Mayo","year":"2016","journal-title":"Adv Radiat Oncol"},{"issue":"36","key":"zoi210049r12","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification.","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi210049r13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain.","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi210049r14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi210049r15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1067\/msy.2000.103883","article-title":"Liver metastases from breast cancer: long-term survival after curative resection.","volume":"127","author":"Selzner","year":"2000","journal-title":"Surgery"},{"issue":"1","key":"zoi210049r16","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases\u2014a population-based study on incidence, management and survival.","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"zoi210049r17","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2010.10.005","article-title":"Liver antigen-presenting cells.","volume":"54","author":"Crispe","year":"2011","journal-title":"J Hepatol"},{"issue":"5","key":"zoi210049r18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC.","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"zoi210049r19","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1001\/jamaoncol.2019.2187","article-title":"Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab.","volume":"5","author":"Topalian","year":"2019","journal-title":"JAMA Oncol"},{"issue":"9","key":"zoi210049r20","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/bjc.2017.70","article-title":"Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.","volume":"116","author":"Nosrati","year":"2017","journal-title":"Br J Cancer"},{"issue":"4","key":"zoi210049r21","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4065\/82.4.490","article-title":"Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment.","volume":"82","author":"Markovic","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"zoi210049r22","doi-asserted-by":"publisher","first-page":"981","DOI":"10.4065\/mcp.2011.0287","article-title":"Circulating serologic and molecular biomarkers in malignant melanoma.","volume":"86","author":"Palmer","year":"2011","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"zoi210049r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CMR.0000000000000520","article-title":"Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.","volume":"29","author":"Petrelli","year":"2019","journal-title":"Melanoma Res"},{"issue":"7355","key":"zoi210049r24","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"issue":"9","key":"zoi210049r25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00262-018-2195-z","article-title":"Targeting tumor-associated acidity in cancer immunotherapy.","volume":"67","author":"Lacroix","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"zoi210049r26","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi210049r27","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/cncr.31889","article-title":"Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy.","volume":"125","author":"Saab","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"zoi210049r30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40425-018-0344-8","article-title":"Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.","volume":"6","author":"Morrison","year":"2018","journal-title":"J Immunother Cancer"},{"key":"zoi210049r31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3389\/fonc.2018.00270","article-title":"Biomarkers for immune checkpoint inhibitors in melanoma.","volume":"8","author":"Kitano","year":"2018","journal-title":"Front Oncol"},{"key":"zoi210049r28","unstructured":"ClinicalTrials.gov. Dabrafenib and trametinib followed by ipilimumab and nivolumab or ipilimumab and nivolumab followed by dabrafenib and trametinib in treating patients with stage III-IV BRAFV600 melanoma. Updated January 27, 2021. Accessed February 2, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02224781"},{"key":"zoi210049r29","unstructured":"ClinicalTrials.gov. Sequential Combo Immuno and Target Therapy (SECOMBIT) Study. Updated June 10, 2019. Accessed February 2, 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02631447?term=NCT02631447&draw=2&rank=1"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2777215\/waninger_2021_oi_210049_1614626832.91634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T21:30:57Z","timestamp":1671571857000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2777215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,9]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0980","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,9]]}}}